NASDAQ:PMN Promis Neurosciences (PMN) Stock Price, News & Analysis $14.01 +0.55 (+4.09%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$14.00 -0.02 (-0.11%) As of 09/18/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Promis Neurosciences Stock (NASDAQ:PMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Promis Neurosciences alerts:Sign Up Key Stats Today's Range$13.52▼$14.2150-Day Range$11.72▼$15.3652-Week Range$6.27▼$27.40Volume23,986 shsAverage Volume39,602 shsMarket Capitalization$125.67 millionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview ProMIS Neurosciences Inc. is a biotechnology company focused on developing therapeutics for neurodegenerative diseases. The company uses its Misfolded Protein Targeting platform to identify toxic forms of proteins associated with disease while aiming to avoid binding to their normal, healthy counterparts. ProMIS’s lead program is PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers implicated in Alzheimer’s disease. The company is also researching antibody-based approaches for other neurodegenerative conditions, including diseases associated with misfolded TDP-43 proteins, such as amyotrophic lateral sclerosis and frontotemporal dementia. Headquartered in Toronto, Canada, ProMIS conducts research and clinical development activities in the biotechnology and neuroscience sectors, with its programs intended for potential global use. The company’s scientific leadership includes co-founder and Chief Scientific Officer Neil Cashman, whose research has focused on misfolded proteins and neurodegenerative disease.AI Generated. May Contain Errors. Read More Promis Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScorePMN MarketRank™: Promis Neurosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 297th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPromis Neurosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPromis Neurosciences has a consensus price target of $34.00, representing about 142.7% upside from its current price of $14.01.Amount of Analyst CoveragePromis Neurosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Promis Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Promis Neurosciences are expected to grow in the coming year, from ($5.14) to ($3.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Promis Neurosciences is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Promis Neurosciences is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Promis Neurosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.99% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 9.41.Change versus previous monthShort interest in Promis Neurosciences has recently decreased by 6.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPromis Neurosciences does not currently pay a dividend.Dividend GrowthPromis Neurosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for PMN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Promis Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Promis Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Promis Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMN Stock News HeadlinesProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberSeptember 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)August 22, 2026 | theglobeandmail.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 13, 2026 | finanznachrichten.deProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 13, 2026 | globenewswire.comVertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product MomentumAugust 4, 2026 | gurufocus.comProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026August 3, 2026 | globenewswire.comSmall-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's StudyJuly 28, 2026 | benzinga.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? Promis Neurosciences' stock was trading at $6.8250 on January 1st, 2026. Since then, PMN shares have increased by 105.3% and is now trading at $14.01. How were Promis Neurosciences' earnings last quarter? Promis Neurosciences (NASDAQ:PMN) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.10. Read the conference call transcript. When did Promis Neurosciences' stock split? Shares of Promis Neurosciences reverse split on Friday, November 28th 2025.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Promis Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Promis Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Trimble (TRMB). Company Calendar Last Earnings8/13/2026Today9/20/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, PMN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PMN CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees11Year Founded2001Price Target and Rating Average Price Target for Promis Neurosciences$34.00 High Price Target$69.00 Low Price Target$18.00 Potential Upside/Downside+142.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($8.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-143.09% Return on Assets-109.15% Debt Debt-to-Equity RatioN/A Current Ratio7.85 Quick Ratio7.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-24.16Miscellaneous Outstanding Shares8,970,000Free Float8,833,000Market Cap$125.67 million OptionableNot Optionable Beta-0.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PMN) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
